Unwin N, Gan D, Whiting D. The IDF Diabetes Atlas: providing evidence, raising awareness and promoting action. Diabetes Res Clin Pract. 2010;87:2–3.

Article  PubMed  Google Scholar 

Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–34.

Article  CAS  PubMed  Google Scholar 

Lee CD, Folsom AR, Pankow JS, Brancati FL. Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. Circulation. 2004;109:855–60.

Article  PubMed  Google Scholar 

Tate M, Grieve DJ, Ritchie RH. Are targeted therapies for diabetic cardiomyopathy on the horizon? Clin Sci (Lond). 2017;131:897–915.

Article  CAS  PubMed  Google Scholar 

Tan Y, Zhang Z, Zheng C, Wintergerst KA, Keller BB, Cai L. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nat Rev Cardiol. 2020;17:585–607.

Article  PubMed  PubMed Central  Google Scholar 

Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia. 2014;57:660–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu S, Yang N, Guan Y, Wang X, Zang G, Lv X, et al. GDF15 promotes glioma stem cell-like phenotype via regulation of ERK1/2-c-Fos-LIF signaling. Cell Death Discov. 2021;7:3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gordon JW, Shaw JA, Kirshenbaum LA. Multiple facets of NF-κB in the heart: to be or not to NF-κB. Circ Res. 2011;108:1122–32.

Article  CAS  PubMed  Google Scholar 

Lei L, Hu H, Lei Y, Feng J. Leukocytic toll-like receptor 2 knockout protects against diabetes-induced cardiac dysfunction. Biochem Biophys Res Commun. 2018;506:668–73.

Article  CAS  PubMed  Google Scholar 

Zhao M-X, Zhou B, Ling L, Xiong X-Q, Zhang F, Chen Q, et al. Salusin-β contributes to oxidative stress and inflammation in diabetic cardiomyopathy. Cell Death Dis. 2017;8:e2690.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Holmes E, Li JV, Marchesi JR, Nicholson JK. Gut microbiota composition and activity in relation to host metabolic phenotype and disease risk. Cell Metab. 2012;16:559–64.

Article  CAS  PubMed  Google Scholar 

Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science. 2012;336:1268–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Witkowski M, Weeks TL, Hazen SL. Gut microbiota and cardiovascular disease. Circ Res. 2020;127:553–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rosser EC, Mauri C. A clinical update on the significance of the gut microbiota in systemic autoimmunity. J Autoimmun. 2016;74:85–93.

Article  CAS  PubMed  Google Scholar 

Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490:55–60.

Article  CAS  PubMed  Google Scholar 

Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761–72.

Article  CAS  PubMed  Google Scholar 

Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol. 2014;11:255–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu N, Zhang Y. TLR4 knockout attenuated high fat diet-induced cardiac dysfunction via NF-κB/JNK-dependent activation of autophagy. Biochim Biophys Acta Mol Basis Dis. 2017;1863:2001–11.

Article  CAS  PubMed  Google Scholar 

Wang S, Ge W, Harns C, Meng X, Zhang Y, Ren J. Ablation of toll-like receptor 4 attenuates aging-induced myocardial remodeling and contractile dysfunction through NCoRI-HDAC1-mediated regulation of autophagy. J Mol Cell Cardiol. 2018;119:40–50.

Article  CAS  PubMed  Google Scholar 

Du G, Sun L, Zhao R, Du L, Song J, Zhang L, et al. Polyphenols: Potential source of drugs for the treatment of ischaemic heart disease. Pharm Ther. 2016;162:23–34.

Article  CAS  Google Scholar 

Liao HH, Zhu JX, Feng H, Ni J, Zhang N, Chen S, et al. Myricetin possesses potential protective effects on diabetic cardiomyopathy through inhibiting IkappaBalpha/NFkappaB and enhancing Nrf2/HO-1. Oxid Med Cell Longev. 2017;2017:8370593.

Article  PubMed  PubMed Central  Google Scholar 

Shen L, Ji H-F. Intestinal microbiota and metabolic diseases: pharmacological implications. Trends Pharm Sci. 2016;37:169–71.

Article  CAS  PubMed  Google Scholar 

Sun WL, Li XY, Dou HY, Wang XD, Li JD, Shen L, et al. Myricetin supplementation decreases hepatic lipid synthesis and inflammation by modulating gut microbiota. Cell Rep. 2021;36:109641.

Article  CAS  PubMed  Google Scholar 

Dong S, Zhu M, Wang K, Zhao X, Hu L, Jing W, et al. Dihydromyricetin improves DSS-induced colitis in mice via modulation of fecal-bacteria-related bile acid metabolism. Pharm Res. 2021;171:105767.

Article  CAS  Google Scholar 

Zhong X, Wang T, Xie Y, Wang M, Zhang W, Dai L, et al. Activated protein C ameliorates diabetic cardiomyopathy modulating OTUB1/YB-1/MEF2B axis. Front Cardiovasc Med. 2021;8:758158.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang G, Wei J, Liu P, Zhang Q, Tian Y, Hou G, et al. Role of the gut microbiota in type 2 diabetes and related diseases. Metabolism. 2021;117:154712.

Article  CAS  PubMed  Google Scholar 

Loo YT, Howell K, Chan M, Zhang P, Ng K. Modulation of the human gut microbiota by phenolics and phenolic fiber-rich foods. Compr Rev Food Sci Food Saf. 2020;19:1268–98.

Article  CAS  PubMed  Google Scholar 

Cunningham AL, Stephens JW, Harris DA. Gut microbiota influence in type 2 diabetes mellitus (T2DM). Gut Pathog. 2021;13:50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

The Integrative Human Microbiome Project. Nature. 2019;569:641-8.

Kootte RS, Vrieze A, Holleman F, Dallinga-Thie GM, Zoetendal EG, de Vos WM, et al. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus. Diabetes Obes Metab. 2012;14:112–20.

Article  CAS  PubMed  Google Scholar 

Vitale M, Giacco R, Laiola M, Della Pepa G, Luongo D, Mangione A, et al. Acute and chronic improvement in postprandial glucose metabolism by a diet resembling the traditional Mediterranean dietary pattern: can SCFAs play a role? Clin Nutr. 2021;40:428–37.

Article  CAS  PubMed  Google Scholar 

Tao Y-W, Gu Y-L, Mao X-Q, Zhang L, Pei Y-F. Effects of probiotics on type II diabetes mellitus: a meta-analysis. J Transl Med. 2020;18:30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peng L, Li Z-R, Green RS, Holzman IR, Lin J. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr. 2009;139:1619–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 2016;7:189–200.

Article  PubMed  PubMed Central  Google Scholar 

den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud D-J, Bakker BM. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res. 2013;54:2325–40.

Article  Google Scholar 

D’Souza WN, Douangpanya J, Mu S, Jaeckel P, Zhang M, Maxwell JR, et al. Differing roles for short chain fatty acids and GPR43 agonism in the regulation of intestinal barrier function and immune responses. PLoS ONE. 2017;12:e0180190.

Article  PubMed  PubMed Central  Google Scholar 

Ruiz-Núñez B, Pruimboom L, Dijck-Brouwer DAJ, Muskiet FAJ. Lifestyle and nutritional imbalances associated with Western diseases: causes and consequences of chronic systemic low-grade inflammation in an evolutionary context. J Nutr Biochem. 2013;24:1183–201.

Article  PubMed